Publication: The clinical efficacy of artemether/lumefantrine (Coartem)
Issued Date
2009-10-12
Copyright Date
2009
Resource Type
Language
eng
ISSN
1475-2875 (electronic)
Rights
Mahidol University
Rights Holder(s)
BioMed Central
Bibliographic Citation
Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5.
Suggested Citation
Makanga, Michael, Srivicha Krudsood, ศรีวิชา ครุฑสูตร The clinical efficacy of artemether/lumefantrine (Coartem). Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar J. 2009 Oct 12;8 Suppl 1:S5.. doi:10.1186/1475-2875-8-S1-S5 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/737
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The clinical efficacy of artemether/lumefantrine (Coartem)
Corresponding Author(s)
Abstract
Current World Health Organization (WHO) guidelines for the treatment of
uncomplicated falciparum malaria recommend the use of artemisinin-based
combination therapy (ACT). Artemether/lumefantrine is an ACT prequalified by the
WHO for efficacy, safety and quality, approved by Swissmedic in December 2008 and
recently approved by the USA FDA. Coartem is a fixed-dose combination of
artemether and lumefantrine. Its two components have different modes of action
that provide synergistic anti-malarial activity. It is indicated for the
treatment of infants, children and adults with acute, uncomplicated infection due
to Plasmodium falciparum or mixed infections including P. falciparum. A
formulation with improved palatability has been developed especially for children
(Coartem Dispersible), which rapidly disperses in a small amount of water for
ease of administration. The efficacy of the six-dose regimen of
artemether/lumefantrine has been confirmed in many different patient populations
around the world, consistently achieving 28-day PCR (polymerase chain
reaction)-corrected cure rates of >95% in the evaluable population, rapidly
clearing parasitaemia and fever, and demonstrating a significant gametocidal
effect, even in areas of widespread parasite resistance to other antimalarials.